Treatment of myelodysplastic syndrome with 1.25-dihydroxy-vitamin D3
โ Scribed by Dr. C. Richard; E. Mazo; M. A. Cuadrado; A. Iriondo; C. Bello; M. A. Gandarillas; A. Zubizarreta
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 200 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
1โฃ,25(OH) 2 D 3 is an important negative regulator of parathyroid hormone (PTH) gene transcription. In parathyroid cells, as in other target tissues, 1โฃ,25(OH) 2 D 3 is degraded by side chain oxidation by the inducible 24-hydroxylase. We have previously shown that one metabolite of this pathway, 1โฃ,
A three-dimensional model for residues 142-427 of the ligand binding domain (LBD) of the human nuclear receptor for 1โฃ,25-dihydroxy-vitamin D 3 [VDR] has been generated based on the X-ray crystallographic atomic coordinates of the LBD of the rat โฃ1 thyroid receptor (TR). The VDR LBD model is an elon